Ixabepilone in modern therapy of resistant breast cancer

Ixabepilone is an epothilone analog, active as a cytotoxic agent due to its ability to stabilize microtubules of tumor cells. Currently ixabepiloneis approved for treatment of metastatic breast cancer in patients previously treated with taxanes and anthracyclines. In this article we analyzed existing data about its efficacy in preoperative and adjuvant treatment settings as well as in systemic therapy of metastatic breast cancer. We discussed a role of ixabepilone in contemporary treatment of this disease.